PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26996132-8	2016	We further revealed that DFO treatment significantly inhibited the MPTP-induced phosphorylation of the c-Jun N-terminal kinase (JNK) and differentially enhanced the phosphorylation of extracellular regulated protein kinases (ERK) and mitogen-activated protein kinase (MAPK)/P38 kinase.	Deferoxamine	25-28	mitogen-activated protein kinase 14	Mus musculus	274-277	
27733186-10	2016	Treatment with DFO significantly reduced neuroinflammation and improved cognitive decline by modulating p38 MAPK signaling, reactive oxygen species, and pro-inflammatory cytokines release.	Deferoxamine	15-18	mitogen-activated protein kinase 14	Mus musculus	104-107	
27787522-8	2016	In addition, blocking of p38 mitogen-activated protein kinase (p38MAPK) signaling pathway promoted DFO-induced HO-1 expression, implicating that p38 signaling pathway was involved in DFO-mediated HO-1 expression.	Deferoxamine	99-102	mitogen-activated protein kinase 14	Mus musculus	25-61	
27787522-8	2016	In addition, blocking of p38 mitogen-activated protein kinase (p38MAPK) signaling pathway promoted DFO-induced HO-1 expression, implicating that p38 signaling pathway was involved in DFO-mediated HO-1 expression.	Deferoxamine	99-102	mitogen-activated protein kinase 14	Mus musculus	63-70	
27787522-8	2016	In addition, blocking of p38 mitogen-activated protein kinase (p38MAPK) signaling pathway promoted DFO-induced HO-1 expression, implicating that p38 signaling pathway was involved in DFO-mediated HO-1 expression.	Deferoxamine	99-102	mitogen-activated protein kinase 14	Mus musculus	25-28	
27787522-8	2016	In addition, blocking of p38 mitogen-activated protein kinase (p38MAPK) signaling pathway promoted DFO-induced HO-1 expression, implicating that p38 signaling pathway was involved in DFO-mediated HO-1 expression.	Deferoxamine	183-186	mitogen-activated protein kinase 14	Mus musculus	25-61	
27787522-8	2016	In addition, blocking of p38 mitogen-activated protein kinase (p38MAPK) signaling pathway promoted DFO-induced HO-1 expression, implicating that p38 signaling pathway was involved in DFO-mediated HO-1 expression.	Deferoxamine	183-186	mitogen-activated protein kinase 14	Mus musculus	63-70	
27787522-8	2016	In addition, blocking of p38 mitogen-activated protein kinase (p38MAPK) signaling pathway promoted DFO-induced HO-1 expression, implicating that p38 signaling pathway was involved in DFO-mediated HO-1 expression.	Deferoxamine	183-186	mitogen-activated protein kinase 14	Mus musculus	25-28	
27787522-9	2016	Taken together, our results suggested that DFO inhibited UHMWPE particles-induced osteolysis by restraining inflammatory osteoclastogenesis through upregulation of HO-1 via p38MAPK pathway.	Deferoxamine	43-46	mitogen-activated protein kinase 14	Mus musculus	173-180	
26996132-10	2016	In SH-SY5Y cells, the DFO-mediated up-regulation of HIF-1alpha occurred via the activation of the ERK and P38MAPK signaling pathway.	Deferoxamine	22-25	mitogen-activated protein kinase 14	Mus musculus	106-113	
26082716-7	2015	Western blotting studies revealed that DFO differentially enhanced the phosphorylation of mitogen-activated protein kinase (MAPK)/P38 kinase in vitro and in vivo.	Deferoxamine	39-42	mitogen-activated protein kinase 14	Mus musculus	130-133	
26082716-8	2015	The results suggest that the DFO may up-regulate several HIF-1-dependent neuroprotective-adaptive genes in AD via activating P38/HIF-1alpha pathway, which may serve as important therapeutic targets to the disease.	Deferoxamine	29-32	mitogen-activated protein kinase 14	Mus musculus	125-128	
24184387-4	2014	Administration of deferoxamine or KC7F2 to hypoxic microglial cells enhanced extracellular signal-regulated kinase (ERK) phosphorylation (p-ERK), but decreased the phosphorylation of p38 (p-p38).	Deferoxamine	18-30	mitogen-activated protein kinase 14	Mus musculus	183-186	
24184387-4	2014	Administration of deferoxamine or KC7F2 to hypoxic microglial cells enhanced extracellular signal-regulated kinase (ERK) phosphorylation (p-ERK), but decreased the phosphorylation of p38 (p-p38).	Deferoxamine	18-30	mitogen-activated protein kinase 14	Mus musculus	190-193	
35237325-8	2022	In conclusion, DFO inhibited the proliferation and ALL xenograft tumor growth, obstructed the cell cycle, and induced apoptosis of ALL cells, probably via inactivating the ROS/HIF-1alpha, Wnt/beta-catenin, and p38MAPK/ERK signaling.	Deferoxamine	15-18	mitogen-activated protein kinase 14	Mus musculus	210-217	
26277391-3	2015	We then found that DFO inhibited phosphorylation of MAP kinases such as ERK and p38 and also inhibited the activation of NF-kappaB induced by LPS.	Deferoxamine	19-22	mitogen-activated protein kinase 14	Mus musculus	80-83	
26082716-0	2015	Intranasal deferoxamine attenuates synapse loss via up-regulating the P38/HIF-1alpha pathway on the brain of APP/PS1 transgenic mice.	Deferoxamine	11-23	mitogen-activated protein kinase 14	Mus musculus	70-73	
24184387-7	2014	This suggests that the anti-inflammatory effect exhibited by deferoxamine is by inhibition of p-p38 induced inflammation through the pERK-pCREB-MKP1 pathway, whereas that of KC7F2 requires further investigation.	Deferoxamine	61-73	mitogen-activated protein kinase 14	Mus musculus	96-99	
35237325-0	2022	Deferoxamine Inhibits Acute Lymphoblastic Leukemia Progression through Repression of ROS/HIF-1alpha, Wnt/beta-Catenin, and p38MAPK/ERK Pathways.	Deferoxamine	0-12	mitogen-activated protein kinase 14	Mus musculus	123-130